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INTRODUCTION 
The occurrence of antinuclear antibodies and lupus 
like syndromes in patients with epilepsy has 
traditionally been regarded as a consequence of 
antiepileptic drugs. However, in the recent years, 
the role of autoimmunity in the pathogenesis of 
epilepsy has been the focus of many studies1. 
Autoantibodies such as those directed against the 
GM1 ganglioside2 and antibodies against the 
GLUR3 receptor subunit3 have been reported in the 
sera of patients with epilepsy, but the possibility 
that epilepsy per se might be associated with 
immunologic alterations and the production of 
autoantibodies has not been sufficiently addressed. 
Several studies have reported high percentages of 
antiphospholipid (aPL) antibodies in patients with 
epilepsy4,5,6. However, it is still not clear if these 
autoantibodies are only an epiphenomenon or 
whether they have a true pathogenic role. 
The aim of this study was to investigate the 
expression of antiphospholipid antibodies [anti β2 
glycoprotein I (IgM and IgG) and anticardiolipin 
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antibodies (IgM and IgG)] in pediatric patients with 
primary epilepsy and to find out whether they have 
any relation to the type of seizures, duration of the 
disease or the  antiepileptic drugs used to achieve 
disease control.  
  
METHODS 
The present study was carried out at the Neurology 
Unit of the Children’s Hospital of Ain Shams 
University in the period from November 2002 to 
June 2003. It included 37 children and adolescents 
diagnosed with primary epilepsy and are regular 
attendees of the Unit's Clinic, and the sample was 
enrolled consecutively. They were 23 males and 14 
females and their ages ranged between 2 to 16 years 
with a mean of 7.4± 4.0 years. 
For comparison, a control group of ten 
clinically healthy children matching the patients in 
age and sex were recruited in the study. They were 
6 males and 4 females, with ages ranging between 2 
and 15 years and a mean age  of 8.1±3.5 years. The 
local ethical committee approved the study and 
consents were taken from the parent(s) of the 
enrolled subjects. 
Inclusion criteria of the patients:  
• Patients with no evidence of definite remote 
cause for epilepsy, that is patients with primary 
epilepsy. According to the recommendations of 
International League Against Epilepsy 7, most of 
our patients were diagnosed as having idiopathic 
epilepsy; only 7 patients had cryptogenic 
epilepsy. 
• Patients with normal liver function tests, renal 
function tests, blood picture, electrolytes, blood 
glucose, metabolic screen and neuroimaging of 
the brain.  
Exclusion criteria of the patients : 
• Patients with history or investigations that 
confirmed a remote and definite CNS insult that 
underlies the epilepsy syndrome i.e. patients with 
symptomatic epilepsy.  
• Any patient whose medical history, examination 
or laboratory investigations could suggest 
autoimmune pathology or previous thrombosis. 
• Patients with current infection till cured. 
Included patients were subjected to the following: 
1-Clinical evaluation: Detailed history was taken 
from each patient by interviewing him and the parents 
and by examining hospital records, laying stress on 
the patient’s age, duration of epilepsy, type of the 
seizure disorder and seizure frequency. Twenty-
seven patients were on regular antiepileptic drug 
therapy (AED), while ten were enrolled as having 
newly- onset idiopathic epilepsies. These were 
included within one month of onset of symptoms; 
none was on therapy at the time of evaluation. The 
AEDs received and the degree of seizure control 
were included. The disease was considered 
controlled if there were no seizures for at least 4 
months prior to enrollment. Patients were carefully 
examined laying stress on the neurologic 
examination and features of autoimmune disorders.  
2-Investigations: 
• Laboratory investigations needed for diagnosis and 
follow up were performed; for e.g. complete blood 
count using coulter counter (T660, USA), hepatic 
and renal function tests, serum levels of calcium, 
sodium, potassium and fasting blood glucose 
using  Synchrone CX5 system (Beckman Inst., 
California, USA). 
• Interictal wake and sleep EEG tracings with photic 
and (whenever possible) hyperventilation 
provocation were performed for all patients 
(Telefactor, PA, USA). Neuroimaging studies (CT 
brain and in some cases magnetic resonance imaging 
(MRI) of the brain) were done as well (MR-max 
500, Genenral Electric, USA). 
• Anticardiolipin (IgG and IgM) were measured for 
the patients and the control groups using ELISA 
technique (Reads Medical Products, Colorado, 
USA). Results were obtained by reading the optic 
density (OD) absorbance using a 
spectrophotometer. Calibrator sera were provided, 
with the aCL concentration expressed in IgG 
phospholipid (GPL) or IgM phospholipid (MPL) 
units, according to the recommendations 
developed at the workshop on standardization and 
interpretation of anticardiolipin test results 8. The 
O.D. values of all the other samples were 
multiplied by the conversion factor to obtain aCL 
antibody concentrations in standard units. Results 
were considered positive for the studied antibody 
if the aCl values were ≥ 23 GPL for IgG and ≥ 11 
MPL for IgM antibodies. 
• Anti-β2-glycoprotein I (IgG and IgM) were 
measured by indirect solid phase enzyme 
immunometric assay (Orgentec Diagnostika 
GmbH, Mainz, Germany)9. It is designed for the 
quantitative measurement of IgG or IgM class 
autoantibodies directed against β2-glycoprotein I. 
For anti-β2-glycoprotein I IgG and IgM a 4- 
Parameter-Fit with lin-log coordinates for optical 
density and concentration is the data reduction 
method of choice. Results were considered 
positive if anti-β2-glycoprotein I  values were > 8 
U/ml, borderline if 5-8 and normal if < 5 U/ml. 
Statistical analysis: 
Data were analyzed by a standard computer 
program  using IBM (SPSS for windows). Results 
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were expressed as mean ± SD or %. The Chi Square 
test (χ2) was used to discriminate the difference in  
descriptive laboratory data. The t test was employed 
in comparing the numerical data of different patient 
groups. Correlation of different numerical variables 
was attempted using Spearman r correlation 
coefficient test. From statistical tables, the 
probability (p) values were calculated; p values less 
than 0.05 were considered significant. 
 
RESULTS 
Clinical features of the included patients are 
summarized in Table (1). The mean disease 
duration was 3.3±2.5 years, ranging from one 
month to 9 years. Ten of the included patients had 
newly diagnosed epilepsy. According to detailed 
history and EEG findings, 12 patients were 
classified as having generalized seizures and 25 
patients as having focal seizures (with or without 
secondary generalization). According to the 
presumed etiology, 30 patients were classified as 
having idiopathic epilepsy syndromes and 7 as 
having cryptogenic syndromes, all of the latter 
group with focal seizures.  
Anticardiolipin (aCL) IgG antibodies were detected 
at a value higher than 23 GPL units in 2 (5.4%) of 
the 37 patients, while anticardiolipin IgM 
antibodies were detected at a value higher than 11 
MPL units in only one (2.7%) patient. None of the 
control sera was positive for anticardiolipin 
antibodies. 
Antiβ2-glycoprotein I (aβ2GP I) IgG antibodies 
were positive in 13 (35.1%) patients, borderline in 
12 (32.4%) and negative in 12 (32.4%) and were 
positive in 10% of the control sera and borderline in 
40% of them. On the other hand, antiβ2 
glycoprotein I IgM antibodies were positive in 
18.9% (7 patients), borderline in 13.5% and 
negative in 67.6% of the patients and were negative 
in all the control sera (Figure 1). 
The mean aCL IgG in the patients group (mean= 
11.32±6.3 GPL) was significantly higher than the 
controls (mean= 5.25±1.9 GPL) (t=5.51, p<0.0001), 
while there was no statistically significant 
difference between cases and controls as regards the 
mean aCL IgM (mean= 3.81±1.8 and 4.21± 2.0 
MPL, respectively). On the other hand, the mean 
aβ2GP I IgM values showed a significantly higher 
value among patients (mean= 4.43±2.8 U/ml) 
compared to controls (1.6±0.6 U/ml) (t=4.9, 
p<0.0001), while there was no significant 
difference in the values of aβ2GP I IgG when 
comparing both groups (mean= 7.21±6.6 and 5.51± 
1.9 U/ml, respectively) (Figure 2). 
Patients with generalized seizures were comparable 
to those with focal seizures in terms of the mean 
values of antibodies tested or their positivity rates. 
The same was observed on comparing patients with 
idiopathic to those with cryptogenic epilepsy. 
Sixty percent of patients with newly diagnosed 
epilepsy showed positivity for at least one of the 
tested antibodies [anticardiolipin antibodies IgG 
(10%), antiβ2glycoprotein I IgG (50%), and anti 
β2glycoprotein I IgM (30%)]. They also showed 
significantly higher mean values of aβ2GP I IgG 
(10.7± 11 U/ml) and aβ2GP I IgM (5.8 ± 3.0 U/ml) 
when compared to the rest of patients (mean 5.9 ± 
3.5, 3.9 ± 2.6 U/ml respectively)(t= 2.2 and 2.08, 
p= 0.03 and 0.04, respectively). The mean values of 
aCL (IgG or IgM) antibodies showed no significant 
difference in between both groups (Figure 3). 
There was no statistical difference between patients 
on valproate and those on carbamazepin or between 
patients on monotherapy and those on polytherapy 
in the mean values of antibodies tested or their 
positivity rates. Moreover, the antibody results were 
not influenced by achievement of seizure control in 
the studied sample. 
The concentrations of the studied antibodies did not 
correlate to the age of patients, age at onset of the 
disease, its duration, or the frequency of the 
seizures.  
 
Table 1: Clinical data of the patients group 
Variable Results 






Age [mean ±SD] 7.4 ± 4.0 












Age of onset in years [mean ±SD] 4.4 ± 3.9 
Duration in years [mean ±SD] 3.3 ± 2.5 













   11 (47.8%) 
   12 (52.2%) 
4 (14.8%) 






AEDs: antiepileptic drugs ; no: number. 
 
 










Figure 1: Percentage of patients with positive anti β2 glycoprotein I  IgG (a) and IgM (b) 




















anti β2GP I : anti β2 glycoprotein I;  anti CL: anticardiolipin. 
*p<0.05 (Significant) 
 
Figure 2: The mean values of aCL IgG (GPL) and IgM (MPL) and aβ2GP I IgG and IgM 











anti β2GP I : anti β2 glycoprotein I;  anti CL: anticardiolipin. 
*p<0.05 (Significant) 
 
Figure 3: Variation of the mean values of aCL IgG (GPL) and IgM (MPL) and aβ2GP I IgG and 




Ischemic events such as focal cerebral ischemia are 
the most common neurologic disorders associated 
with aPL antibodies; however, cognitive 
dysfunction, depression, migraine, chorea and 
seizures have all been associated with aPL 
antibodies 10. Recently, it has been suggested that 
interaction between aPL antibodies and central 
nervous system cellular elements rather than aPL - 
associated thrombosis seems to be a more plausible 
mechanism for these clinical manifestations 11,12,13.  
The present work was carried out to investigate the 
prevalence of antiphospholipid antibodies (anti β2 
glycoprotein I and anticardiolipin antibodies) in a 
group of pediatric patients with epilepsy and the 
possible association with the primary type of 
seizure, its duration or the type of antiepileptic 
drugs received. We noticed that 40.5% of the 
patients were positive for at least one of the 
antiphospholipid antibodies and several patients 
(16%) displayed more than one antibody in their 
serum, though none of our patients had evidence of 
thrombosis or autoimmune disease. The aCL IgG 
was considered positive in 5.4% of our series with a 
mean that was significantly higher among patients 
in contrast to aCL IgM, which showed no 
significant difference between patients and controls. 
On the other hand, the mean aβ2GP I IgM was 
significantly higher among patients, while aβ2GP I 
IgG showed no significant difference between 
patients and controls. 
Verrot et al. 4 found a prevalence of 19% of aCL 
antibodies, in patients with epilepsy, values that 
were significantly higher than their control group, 
though none of their patients revealed clinical 
symptoms of SLE, or clinical features of primary 
antiphospholipid antibody syndrome (APS). Similar 
to our results, it was the IgG isotype that showed 
significant difference from the control results, while 
the IgM aCL antibodies were not detected at a 
significant value. Eriksson et al. 14 and Pardo et al. 5, 
in their studies on patients with epilepsy, reported 
even a higher prevalence (44% and 42%, 
respectively) of aPL antibodies. Eight of out nine 
cases of benign infantile convulsions, studied by 
Yoshimura et al. 13, were positive for aCL IgG and 
the values of aCL IgG decreased over long term 
observation in three of these cases. Based on these 
data, they suggested that some immunological 
responses may be responsible for the pathogenesis 
of benign infantile convulsion. 
The real pathogenic significance of aPL antibodies 
in epileptic patients is still unclear. Although it has 
been claimed that aPL antibodies are specific for 
Antiphospholipid antibodies in epilepsy. 
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thrombosis-mediated antiphospholipid events, there 
is evidence that they also bind to brain tissue 11. IgG 
from patients with antiphospholipid syndrome were 
found to induce depolarization of brain 
synaptoneurosomes in animal models, suggesting 
the possibility of a direct and reversible mechanism 
through which antiphospholipid antibodies might 
lower the seizure threshold  15. Meroni et al. 16 
demonstrated that human brain microvascular 
endothelial cells bind higher amounts of β2GP I and 
can be activated by IgG from aPL positive sera and 
by aβ2GP I antibodies. In addition, β2GP I was 
identified immunohistologically on brain cells 11, 
and functional central nervous system involvement 
was reported in experimental models of 
antiphospholipid syndrome 15. Altogether, these 
findings suggest a pathogenic role for aPL 
antibodies in epilepsy, by means of microinfarcts 
secondary to ischemic events, or by an immune 
mediated mechanism directed against endothelial or 
neuronal cells, as suggested in experimental 
models. We cannot argue strongly for the presence 
of epileptogenic cerebral ischemic lesions, a 
mechanism that is frequently invoked. Imaging of 
the brain found no ischemic lesion in our patients, 
however small microinfarcts not visible by imaging 
could not be excluded. The aCL antibodies could 
also reflect a common, perhaps genetically 
determined predisposition1 to develop epilepsy and 
to produce autoantibodies as seems the case for 
aCL antibodies in schizophrenia 17. Another 
putative mechanism might be through an 
autoimmune reaction to antigens expressed 
specifically by neurons that have an epileptic 
activity, as has been demonstrated for several types 
of seizure-induced genes 18 or cell products 19. 
Antiphospholipid antibodies associated with drugs 
have also been described 20.  
Although no enough criteria for drug-induced aCL 
antibodies have been defined, they are usually of 
the IgM isotype, the IgG class aCL antibodies being 
negative or low in titer 21. In the present study, aCL 
antibodies were of the IgG isotype. Whatever the 
mechanism by which the aPL antibodies appear and 
whatever their precise connection with epilepsy 
might be, the risk of thrombotic events and its 
primary prevention must be considered. Indeed, it is 
known that aPL antibodies, even when they are 
induced by drugs, significantly increase the risk of 
both venous and arterial thrombosis 22.  
The type of seizures whether generalized or focal 
did not seem to influence the mean values or the 
positivity of the antibodies tested in our series. A 
similar observation was previously noted 4.On the 
other hand, two other studies  noted that the 
prevalence of antinuclear antibodies and perhaps 
anticardiolipin antibodies is greater in patients with 
localized related epilepsies than those with 
generalized epilepsies 14,23.  Eriksson et al. 14 
reported a positivity of 13% for aPL in children 
with partial epilepsy and they suggested that these 
antibodies may indicate that an immune- mediated 
neuronal damage could be a pathogeneic 
mechanism for partial epilepsy.  
Our patients with idiopathic epilepsy demonstrated 
comparable concentrations and positivity rates of 
aPL antibodies to those with cryptogenic epilepsy. 
Another study reported that the cryptogenic group 
of patients with epilepsy is more presented among 
aPL antibodies- positive patients than the idiopathic 
group6. This may be due to the difference in the 
type of aPL antibodies they investigated, which are 
the antiprothrombin antibodies beside aβ2GP I and 
aCL. 
A substantial prevalence of aPL (aCL and anti-β2 
glycoprotein I) (60%) was noticed among patients 
with newly diagnosed, untreated epileptic seizures 
in our series, which reinforces the concept that the 
occurrence of autoantibodies cannot be due to 
antiepileptic medications alone. Also, there was a 
significantly higher mean values of anti 
β2glycoprotein I IgM and IgG among those new 
cases when compared to the rest of the patients. In 
agreement with our data, Peltola et al. 23 reported a 
significant increase in anticardiolipin antibodies, 
anti β2glycoprotein I antibodies, and antinuclear 
antibodies expression among patients with newly 
diagnosed, untreated epileptic seizures.  Thus, it 
seems that aPL antibodies could be more linked to 
the disease itself than to the medications received.  
Again, there was no significant difference in the 
levels of antibodies tested among patients on 
monotherapy in comparison to those receiving 
polytherapy, neither did the results vary with the 
use of different antiepileptic drugs. Similar 
observations were cited in literature 4,6. The finding 
that aPL antibodies were even higher in patients 
with new onset seizures is supported by the study of 
Yoshimura et al. 11 who noted a decrease in aCL 
IgG by follow up in 37% of patients with benign 
infantile convulsions This might suggest a direct 
role of the aPL in the pathogenesis of epilepsy. 
In the present study, seizure control did not 
significantly influence the expression of the 
antibodies tested. Our results might contradict with 
some previously published data on the association 
between aPL and multiple seizure types 14 and 
frequency of seizures 6. However, it is worth noting 
that both studies included symptomatic epileptic 
syndromes, a group that was excluded in our study. 
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Our findings might also be limited by the small 
sample size.  
In conclusions, the aPL autoantibodies (aβ2GP I 
and aCL) were detected at a significantly higher 
rate in  a group of pediatric patients with primary 
epilepsy than in a matched group of healthy 
children. The increased prevalence of 
autoantibodies is more strongly associated with the 
epilepsy itself than with its type, the antiepileptic 
drugs used or the degree of seizure control, 
indicating that immune dysregulation may be 
associated with epilepsy. Although a direct causal 
relation cannot be advocated at this level, a 
pathogenic role of these antibodies cannot be 
excluded and screening for these antibodies may 
help in early diagnosis of diseases with autoimmune 
background. We thus recommend follow up of 
patients with positive aPL antibodies for 
development of autoimmune disease or thrombotic 
events. A trial of alternative therapeutic approaches 
(immunomodulator drugs) should be considered in 
difficult cases or in patients not responding to 
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